



14 May, 2025

**SYN-TECH CHEM.& PHARM.CO.,LTD**

Industry Forum

Chen-Ming, Hsiao Chairman



生泰合成工業公司  
SYN-TECH CHEM & PHARM CO., LTD

Stock Code : 1777



# Safe Harbor Notice

- ★ **In these presentations and discussions, there are certain forward-looking statements regarding the results of operation, financial condition and current expectation about future events. As forward-looking statements relate to events and depend on circumstances in the future, they involve risk and uncertainty.**
- ★ **We do not undertake any obligation to publicly revise or update any forward looking statements for availability of new information, future events or otherwise. Real result probably differ substantially from those expected in these forward-looking statements.**



# CONTENTS

## Company Brief Introduction

Brief overall  
Main Products  
DMF/MF Registration Status  
Official and Customer Audit Records

## Business and Financial Statements

Performance for operation

## Strategy in the Future Development & forward-looking

Future strategies and forward-looking



01

## Company Brief Introduction

Brief overall

Main Products

DMF/MF Registration Status

Official and Customer Audit Records



# Brief overall

## ● 1982 , Nov. 9 established

- ❑ NT\$ 445,917,130
- ❑ C. M. Hsiao, Chairman
- ❑ 219 employees
- ❑ APIs
- Animal Drugs
- Excipient



## ● ISO

- ❑ ISO 9001
- ❑ ISO 14001
- ❑ ISO 45001
- ❑ PIC/S GMP
- ❑ GDP
- ❑ ISO 14064-1

## ● Awards Record

- ❑ National Award in Medicine Quality
- ❑ National Award of Outstanding
- ❑ Research and Development Award in Pharmaceutical Technology
- ❑ National Innovation Award
- ❑ Industrial Sustainable Excellence Award
- ❑ Small and medium enterprise Innovation Award
- ❑ National Innovation Award renewal
- ❑ 2024 Net-Zero Industry Competitiveness Superior Award

## ● All-round development

- ❑ Manpower cultivation
- ❑ Business fields
- ❑ Infrastructure
- ❑ Cooperate with academic units
- ❑ Develop new drugs with other enterprises



# Main Products

SYN-TECH CHEM. & PHARM. CO. LTD.

Product 1

**Muscle Relaxants**

Product 6

**Respiratory System Drugs**

Product 2

**Digestive System Drugs**

Product 7

**Chemotherapeutic Drugs**

Product 3

**Central Nervous System Drugs**

Product 8

**Cardiovascular Agents**

Product 4

**Topical Anesthetic Agents**

Product 9

**Non- Steroidal Anti- Inflammatory  
Antipyretics and Analgesics**

Product 5

**Excipient and Animal Drugs**

Product 10

**Others**



## DMF/MF Registration Status

SYN-TECH CHEM. & PHARM. CO. LTD.

COUNTRY	DMF/MF (APIs)
U.S.A	18
Japan	16
Canada	3
Korea	5
European Union	6
China	4
Others	9

# Official Audit Records

SYN-TECH CHEM. & PHARM. CO. LTD.

U.S.A FDA  
Number /  
Audit : 7

Korea FDA  
Number /  
Audit : 2

Australia  
TGA  
Number /  
Audit : 4

Mexico  
FDA  
Number /  
Audit : 1

1995

2002

2007

2008

2009

2014

2015

2016

Taiwan FDA  
Number /  
Audit : 21

Hungary FDA  
Number /  
Audit : 1

Japan  
PMDA  
Number /  
Audit : 5

EDQM  
Number /  
Audit : 1



# Customer Audit Records

SYN-TECH CHEM. & PHARM. CO. LTD.

Audit year	Number / Audit
2020	5
2021	7
2022	11
2023	35
2024	38
Jan.- Mar., 2025	9



02

# Business and Financial Statements


Performance for operation



# Revenue of Recent 5 Years

SYN-TECH CHEM. & PHARM. CO. LTD.

Unit : NT in million






# Product Category Revenue Proportion Between 2024 and 2023

SYN-TECH CHEM. & PHARM. CO. LTD.

Unit : NT in ten thousand






# Product Category Revenue Proportion Between 2025 and 2024 Q1

SYN-TECH CHEM. & PHARM. CO. LTD.

Unit : NT in ten thousand




■ Jan.-Mar., 2025	9,534	4,402	4,316	2,590	2,518	2,141	1,246	1,028	270	3,530
■ Jan.-Mar., 2024	11,107	3,126	1,874	680	3,648	3,283	499	2,519	149	93



# Sale proportion basis on the Area

SYN-TECH CHEM. & PHARM. CO. LTD.




■ Asia (Except Taiwan and Japan) ■ Japan ■ America ■ Europe ■ Others ■ Taiwan

**Data collected : Year 2024**



## Sale proportion basis on the Area

SYN-TECH CHEM. & PHARM. CO. LTD.



■ Asia (Except Taiwan and Japan) ■ Japan ■ America ■ Europe ■ Others ■ Taiwan

**Data collected form Jan.- Mar., 2025**

# Revenue Compared Between 2024 and 2023

SYN-TECH CHEM. & PHARM. CO. LTD.

Unit : NT in thousands

Item	2024	2023	Differences (%)
Operating revenue	1,257,665	1,114,687	13
Gross profit	486,941	409,521	19
Gross profit ratio (%)	39	37	5
Operating profit	350,804	281,851	24
Non- operating income and expenses	137,434	31,918	331
Profit before tax	488,238	313,769	56
Profit after tax	393,284	251,013	57
EPS (in dollar)	8.82	5.63	57



# The Differences Between 2024 and 2023

SYN-TECH CHEM. & PHARM. CO. LTD.

## Revenue

- Mainly due to the gradual resumption of product production and sales after the reconstruction of plants, and the increase in exports to Japan, which further promoted the increase in operating revenue.

## Profit

- Mainly due to the active expansion of export markets, the increase in production capacity after the reconstruction of plants, and the adjustment of sales product mix.
- The significant increase in non-operating income was due to a significant increase in claims revenue and currency exchange gains.



# Revenue Compared Between 2025 and 2024 Q1

SYN-TECH CHEM. & PHARM. CO. LTD.

Unit : NT in thousands

Item	Jan.- Mar., 2025	Jan.- Mar., 2024	Differences (%)
<b>Operating revenue</b>	<b>315,750</b>	<b>269,782</b>	<b>17</b>
<b>Gross profit</b>	<b>116,398</b>	<b>104,847</b>	<b>11</b>
<b>Gross profit ratio (%)</b>	<b>37</b>	<b>39</b>	<b>(5)</b>
<b>Operating profit</b>	<b>83,274</b>	<b>74,613</b>	<b>12</b>
<b>Non- operating income and expenses</b>	<b>11,448</b>	<b>34,617</b>	<b>(67)</b>
<b>Profit before tax</b>	<b>94,722</b>	<b>109,230</b>	<b>(13)</b>
<b>Profit after tax</b>	<b>75,751</b>	<b>87,384</b>	<b>(13)</b>
<b>EPS (in dollar)</b>	<b>1.70</b>	<b>1.96</b>	<b>(13)</b>



# The Differences Between 2025 and 2024 Q1

SYN-TECH CHEM. & PHARM. CO. LTD.

## Revenue

- Mainly due to the growth in exports to Japan and increased sales of intermediates.
- Develop new customers and gradually increase sales.

## Profit

- Although revenue grew, gross profit ratio declined due to a change in the product mix sold.
- As the US dollar position decreases, currency exchange gains and interest income decrease, resulting in a decrease in non-operating income.






# EPS and Dividend in Recent 5 Years

SYN-TECH CHEM. & PHARM. CO. LTD.

Unit : NT in dollar





03

## Strategy in the Future Development & forward-looking

Future strategies and forward-looking



# Strategy in the Future Development & forward-looking I

SYN-TECH CHEM. & PHARM. CO. LTD.



- **IMH has completed one batch of validation and is scheduled to complete three batches of validation in the second quarter. AMH's quality has been recognized by Japanese pharmaceutical companies, with sales exceeding 500 KG in the first quarter of this year, and it is estimated that sales this year will exceed 3 tons. DFP has completed the Master File and also achieved 500 KG of sales in the first quarter.**
- **Optimize the product manufacturing process, automate key steps to provide high-quality and affordable products :**
  1. Research and develop to improve the manufacturing process, plan the automation of key steps. CTT have initially completed the improvement plan with the Development Center for Biotechnology (DCB).
  2. The reconstruction of the plant, facilities and equipment was completed, and CMZ, OPS, and PEH increased the revenue by more than NT\$ 12 million in the first quarter.
  3. Special product research and development, TVP products have achieved revenue of NT\$ 12 million in the first quarter.



# Strategy in the Future Development & forward-looking II

SYN-TECH CHEM. & PHARM. CO. LTD.

## ● Carefully select and evaluate suitable new niche APIs for the future development :

In accordance with national needs, products are selected to be manufactured to avoid domestic shortage of drugs. We are still conducting research and development on APB and SBS that are listed in the list of essential drugs. And GSB has completed validation.



## ● Expanding New Business Area :

- Evaluate APIs' key intermediates.
- Develop our business in China market, CTT and AMH.
- Small quantities of specialty APIs, PRX.
- Develop new drugs GFH with other enterprises and have obtained a license.



SYN-TECH CHEM. & PHARM. CO., LTD

Thanks for your attention



生泰合成工業公司  
SYN-TECH CHEM & PHARM CO., LTD

Stock Code : 1777